Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol,[1] a novel, once-daily, oral therapy for treating liver diseases[2] utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates (FABACs). Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis (NASH),[3] a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance.[4][5]

Galmed Pharmaceuticals, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABACs and NASH.[6]

References

  1. ↑ "Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH". MarketWatch.com. Retrieved 7 January 2015.
  2. ↑ "Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical". News-medical.net. Retrieved 7 January 2015.
  3. ↑ "UPDATE: MLV & Co Reiterates On Galmed Pharmaceuticals Ltd As Aramchol Grabs FDA Fast Track Designation". Benzinga.com. Retrieved 7 January 2015.
  4. ↑ "Galmed Pharmaceuticals Completes Analysis Of A Pharmacokinetic Study Of Aramchol In Healthy Volunteers". BioSpace.com. Retrieved 7 January 2015.
  5. ↑ "Galmed Pharmaceuticals Ltd.". Nytimes.com. Retrieved 7 January 2015.
  6. ↑ "Galmed's registration with US Securities and Exchange Commission". Sec.gov. Retrieved 7 January 2015.
This article is issued from Wikipedia - version of the Friday, August 14, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.